JP2020530285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530285A5 JP2020530285A5 JP2020500832A JP2020500832A JP2020530285A5 JP 2020530285 A5 JP2020530285 A5 JP 2020530285A5 JP 2020500832 A JP2020500832 A JP 2020500832A JP 2020500832 A JP2020500832 A JP 2020500832A JP 2020530285 A5 JP2020530285 A5 JP 2020530285A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding molecule
- sequence
- domain antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 11
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 11
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 10
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 9
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 9
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000025844 Prostatic disease Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000010324 immunological assay Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1711068.5 | 2017-07-10 | ||
| GBGB1711068.5A GB201711068D0 (en) | 2017-07-10 | 2017-07-10 | Therapeutic molecules binding PSMA |
| PCT/GB2018/051941 WO2019012260A1 (en) | 2017-07-10 | 2018-07-09 | THERAPEUTIC MOLECULES BINDING TO PSMA |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530285A JP2020530285A (ja) | 2020-10-22 |
| JP2020530285A5 true JP2020530285A5 (enExample) | 2021-08-19 |
| JP7346378B2 JP7346378B2 (ja) | 2023-09-19 |
Family
ID=59676551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500832A Active JP7346378B2 (ja) | 2017-07-10 | 2018-07-09 | 治療的ｐｓｍａ結合分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11401342B2 (enExample) |
| EP (1) | EP3652213A1 (enExample) |
| JP (1) | JP7346378B2 (enExample) |
| CN (1) | CN111051348A (enExample) |
| GB (1) | GB201711068D0 (enExample) |
| WO (1) | WO2019012260A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| JP7312168B2 (ja) | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| WO2019232449A1 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
| BR112021010936A2 (pt) | 2018-12-13 | 2021-08-31 | Eisai R&D Management Co., Ltd. | Conjugados anticorpo-fármaco de herboxidieno e métodos de uso |
| AU2020252556B2 (en) * | 2019-04-05 | 2026-02-05 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
| KR20220008839A (ko) * | 2019-05-15 | 2022-01-21 | 크레센도 바이오로직스 리미티드 | 결합 분자 |
| WO2023199069A1 (en) | 2022-04-14 | 2023-10-19 | Crescendo Biologics Limited | Chimeric antigen receptor that binds mesothelin |
| GB202205589D0 (en) | 2022-04-14 | 2022-06-01 | Crescendo Biologics Ltd | Mesothelin binders |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| ES2559002T3 (es) | 2001-10-23 | 2016-02-10 | Psma Development Company, L.L.C. | Anticuerpos contra PSMA |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| GB0313132D0 (en) | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| WO2006089230A2 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| CA2616859C (en) | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| ES2597849T3 (es) | 2007-10-09 | 2017-01-23 | Polytherics Limited | Proteínas y péptidos conjugados novedosos |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
| CN103087171B (zh) | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法 |
| WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| CN103333249A (zh) | 2013-06-14 | 2013-10-02 | 广州康合生物科技有限公司 | 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用 |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| US11547099B2 (en) | 2014-10-22 | 2023-01-10 | Crescendo Biologies Limited | Transgenic mice |
| WO2016063006A1 (en) | 2014-10-24 | 2016-04-28 | Polytherics Limited | Conjugates and conjugating reagents |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| CN105968204B (zh) | 2016-02-03 | 2020-01-21 | 中国人民解放军第三军医大学第一附属医院 | 一种抗前列腺特异性膜抗原的单域重链抗体 |
| CN105968203A (zh) | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105968205B (zh) | 2016-02-03 | 2019-04-26 | 中国人民解放军第三军医大学第三附属医院 | 一种抗前列腺特异性膜抗原的纳米抗体 |
| GB201607968D0 (en) * | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| JP7312168B2 (ja) * | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
-
2017
- 2017-07-10 GB GBGB1711068.5A patent/GB201711068D0/en not_active Ceased
-
2018
- 2018-07-09 EP EP18749051.1A patent/EP3652213A1/en active Pending
- 2018-07-09 CN CN201880055554.8A patent/CN111051348A/zh active Pending
- 2018-07-09 WO PCT/GB2018/051941 patent/WO2019012260A1/en not_active Ceased
- 2018-07-09 US US16/627,968 patent/US11401342B2/en active Active
- 2018-07-09 JP JP2020500832A patent/JP7346378B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530285A5 (enExample) | ||
| JP2019511201A5 (enExample) | ||
| JP2019506155A5 (enExample) | ||
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2009539380A5 (enExample) | ||
| JP2020516603A5 (enExample) | ||
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2016519932A5 (enExample) | ||
| JP2007526233A5 (enExample) | ||
| JP2009533021A5 (enExample) | ||
| RU2014120536A (ru) | Белки специфического связывания и их применения | |
| ES2637151T3 (es) | Tratamiento del linfoma de células T periféricas | |
| JP2020534830A5 (enExample) | ||
| CN111499750B (zh) | 一种抗癌胚抗原的高中和活性纳米抗体及其应用 | |
| JP2014515600A5 (enExample) | ||
| CN108178799B (zh) | 一种抗ca125糖类抗原的纳米抗体及其应用 | |
| CN112094348B (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| JP7357012B2 (ja) | 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法 | |
| CN106164672A (zh) | 用于诊断的细胞表面前列腺癌抗原 | |
| JP2005528884A5 (enExample) | ||
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN117586412A (zh) | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 | |
| CN113150152A (zh) | 一种人源t细胞表面抑制性分子的特异性纳米抗体及其应用 | |
| WO2023207475A1 (zh) | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 | |
| JP2015520172A5 (enExample) |